The Food and Drug Administration on Fridayissued an emergency use authorization for remdesivir, in a bid to help patients get quicker access tothe first antiviral to show promise against Covid-19 infections.
The authorization comes two days after data from a government trialsuggested the experimental drug can help patients recover faster and may reduce death rates compared to a placebo. The nation’s top infectious disease doctor, Anthony Fauci, said the results make remdesivir the new standard of care as researchers continue to develop more effective options.
But he also cautioned that, while the results were encouraging, they represented an early step toward finding effective coronavirus treatments — much as the drug AZT represented the first hope for AIDS patients in the 1980s, but was later supplanted by drastically more effective combination therapies.
An emergency use authorization is not a full approval — the drug must undergo further review — but it allows doctors to use remdesivir outside of clinical trials during the pandemic. FDA has issued emergency authorizations for a range of Covid-19 tests as well as for hydroxychloroquine, a malaria medicine with limited evidence to suggest it can fight the coronavirus. President Donald Trump has called remdesivir a “building block” in progress toward fighting the coronavirus.
The EUA allows the drug to be used for patients with confirmed or suspected coronavirus infections.
“The statutory standard for EUA is very weak,” said Holly Fernandez Lynch, a medical ethics professor at the Perelman School of Medicine at the University of Pennsylvania. “If it was met for [hydroxychloroquine], which was questionable to be honest, it was clearly met here. It’s just ‘may be effective’ based on available evidence.”
Credit: Politico
Comments are closed, but trackbacks and pingbacks are open.